Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-04 · 18 (2)
DOI: 10.1002/dad2.70377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 21.05.2026. Verfasst von Alexander Wallace und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Iowa Hospitals and Clinics Iowa City Iowa USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
INTRODUCTION Lecanemab has demonstrated both safety and efficacy in clinical trials; however, routine clinical data are sparse. We contribute to the growing body of real‐world safety data, with a special focus on amyloid‐related imaging abnormalities (ARIA). METHODS We conducted a retrospective chart review of 146 patients treated with lecanemab according to appropriate‐use recommendations at a specialty memory center clinic. RESULTS Real‐world safety and efficacy data closely resemble published data in the Clarity‐AD trial. Thirty‐three patients (23%) discontinued treatment; all remaining patients completed at least 12 months of treatment. We observed a positive trend toward increasing ARIA edema/effusion (ARIA‐E) with increasing mean arterial pressure and a mean amyloid clearance of −90.6 at 18 months. DISCUSSION When used according to appropriate‐use recommendations, lecanemab is as safe as reported in the Clarity‐AD trial. Further investigation into real‐world data is necessary for a more complete evaluation of lecanemab's safety and efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Iowa Hospitals and Clinics Iowa City Iowa USA.
- Texas A&M College of Medicine Bryan Texas USA.
- Baylor University Medical Center Dallas Texas USA.
- Baylor AT&T Memory Center Dallas Texas USA.
ORCID-Profile: Alexander Wallace
Zitieren
APA
Wallace, A., Zhou, O., Hoang, M. N., Porter, G., Padilla, C., & Marshall, C. (2026). Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(2). https://doi.org/10.1002/dad2.70377
Vancouver
Wallace A, Zhou O, Hoang MN, Porter G, Padilla C, Marshall C. Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(2). doi:10.1002/dad2.70377
BibTeX
@article{Wallace2026,
author = {Wallace, Alexander and Zhou, Oliver and Hoang, Minh-Nguyet and Porter, Gabriella and Padilla, Claudia and Marshall, Cindy},
title = {Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2026},
volume = {18},
number = {2},
doi = {10.1002/dad2.70377}
}
EUVIMED